Critical

Acute exacerbation of IPF (AE-IPF)

ILD emergency · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

An acute (< 1 month) clinically significant worsening of breathlessness in a patient with IPF (or other fibrotic ILD), with NEW bilateral ground-glass opacity / consolidation on HRCT superimposed on the fibrotic background, NOT fully explained by cardiac failure or fluid overload. It may be triggered (infection, aspiration, surgery/biopsy, drugs, pollution) or idiopathic, carries a very high in-hospital mortality (around 50%) and is a leading cause of death in IPF.

Red flags

  • Rapidly rising oxygen requirement / refractory hypoxaemia
  • Haemodynamic instability or multi-organ failure
  • Need for ventilatory support (poor prognosis — triggers ceiling-of-care discussion)
  • Features of a treatable trigger (infection, PE, heart failure) that must not be missed

Assessment

Differential diagnosis

  • Pneumonia / viral LRTI (including influenza, COVID-19)
  • Pulmonary embolism
  • Acute heart failure / fluid overload
  • Aspiration pneumonitis
  • Drug-induced pneumonitis
  • Pneumothorax
  • Progression of fibrosis without DAD

Investigations

  • HRCT chest — new bilateral ground-glass/consolidation on a background of fibrosis (defines the syndrome); compare with prior imaging.
  • Exclude mimics: CTPA for PE, echocardiography/BNP for cardiac failure, respiratory viral PCR (incl. influenza, SARS-CoV-2), sputum/blood cultures, procalcitonin.
  • ABG — degree of hypoxaemic (type 1) respiratory failure.
  • FBC, U&E, CRP, LFTs, BNP, D-dimer; consider bronchoscopy/BAL to exclude infection if it will change management and the patient can tolerate it.

Management

  • Treat as a respiratory emergency: high-flow oxygen; high-flow nasal oxygen (HFNO) is often preferred for comfort and oxygenation.
  • Aggressively look for and treat a reversible trigger — start empirical antibiotics ± antivirals for suspected infection, treat PE, heart failure and aspiration.
  • HIGH-DOSE CORTICOSTEROIDS are commonly used (e.g. IV methylprednisolone pulses) — widely practised but evidence is low-quality; decide case-by-case with respiratory/ILD input.
  • Optimise supportive care: careful fluid balance, VTE prophylaxis, nutrition, treat cough and distressing breathlessness (opioids).
  • Discuss ceiling of care EARLY: invasive mechanical ventilation generally has very poor outcomes in AE-IPF and is usually not appropriate — involve the patient, family and ILD/ICU teams; HFNO or NIV may bridge selected transplant candidates.
  • Continue or (re)start an antifibrotic where appropriate and involve the transplant team urgently for eligible candidates.
  • Integrate palliative care in parallel for symptom control and advance-care planning given the high mortality.

Drugs & doses

High-flow oxygen / high-flow nasal oxygen (HFNO)
Methylprednisolone IV (high-dose pulses) — commonly used, low-quality evidence
Empirical antibiotics per BNF — see the in-app Antibiotic Dosing tool
Opioids for refractory breathlessness; antitussive for cough
VTE prophylaxis

Disposition

Admit under respiratory/ILD; HDU/ICU per ceiling-of-care decision; urgent transplant-team contact for eligible candidates; early palliative-care involvement.

Complications & pitfalls

  • Progressive hypoxaemic respiratory failure and death (~50% in-hospital mortality)
  • Nosocomial infection (compounded by steroids)
  • Barotrauma / poor outcomes with invasive ventilation
  • VTE

Exam pearls

  • New bilateral ground-glass on top of fibrosis, not explained by the heart or fluid, in an IPF patient = acute exacerbation until proven otherwise.
  • Always exclude infection, PE and heart failure first — they are treatable and can masquerade as, or trigger, AE-IPF.
  • High-dose steroids are widely given but the evidence is weak; the biggest early win is finding and treating a trigger plus getting the ceiling-of-care conversation right.
  • Intubation in AE-IPF is usually futile — reserve it, at most, as a bridge for a transplant candidate.

AE-IPF: acute (<1 month) worsening with new bilateral ground-glass on a fibrotic background, not from cardiac failure. High-flow oxygen, aggressively exclude and treat infection/PE/heart failure, high-dose steroids are commonly used (low-quality evidence), and discuss ceiling of care early — invasive ventilation is usually futile. Mortality is around 50%; involve ILD, ICU, transplant and palliative-care teams. Antibiotic doses per BNF (current edition); confirm choice in the in-app Antibiotic Dosing tool.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.